CYSLTR1
ENSG00000173198
Target class
GPCR
Chromosome
X
Approved drugs
3
Clinical candidates (approved and in development)
4
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Target name
- CYSLTR1
- Gene name
- Cysteinyl leukotriene receptor 1
- Gene symbol
- CYSLTR1
- Protein name
- Cysteinyl leukotriene receptor 1 (CysLTR1) (Cysteinyl leukotriene D4 receptor) (LTD4 receptor) (G-protein coupled receptor HG55) (HMTMF81)
- CysLT1
- CysLT(1)
- CYSLT1R
- Gene biotype
- Protein coding
- Gene family
- Leukotriene receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 15
- Highest tissue expression
- 12.06
- Tissue specificity (Gini)
- 0.649
- Tissue specificity (tau)
- 0.921
- KEGG gene identifiers
- hsa:10800
- Protein interaction confidence
- 0.805111
- Protein interaction partners
- 9
- R-HSA-391906
- R-HSA-416476
- R-HSA-9664535
- R-HSA-9679191
- End position
- 78327691
- Start position
- 78271468
- Chromosome
- X
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.921352
- Expression inequality (Gini)
- 0.649414
Expression in transcripts per million
- Esophagus - Muscularis
- 12.06
- Esophagus - Gastroesophageal Junction
- 8.94
- Spleen
- 4.55
- Cells - EBV-transformed lymphocytes
- 4.48
- Adipose - Subcutaneous
- 2.28
Expression in transcripts per million
- Esophagus - Muscularis12.06
- Esophagus - Gastroesophageal Junction8.94
- Spleen4.55
- Cells - EBV-transformed lymphocytes4.48
- Adipose - Subcutaneous2.28
- Adipose - Visceral (Omentum)1.95
- Small Intestine - Terminal Ileum1.93
- Breast - Mammary Tissue1.75
- Thyroid1.74
- Artery - Coronary1.59
- Lung1.43
- Whole Blood1.41
- Minor Salivary Gland1.37
- Artery - Aorta1.12
- Nerve - Tibial1.11
- Prostate0.87
- Colon - Transverse0.87
- Esophagus - Mucosa0.84
- Bladder0.83
- Fallopian Tube0.82
- Stomach0.82
- Uterus0.71
- Colon - Sigmoid0.67
- Skin - Not Sun Exposed (Suprapubic)0.66
- Vagina0.62
And 29 more, listed on the interactive page.
- GO:0006952
- GO:0007204
- GO:0007585
- GO:0005886
- GO:0016020
Molecular functions
- GO:0004974
Related records
Trials (317)
- A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber
- A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)
- A Drug Interaction Study of Montelukast and Levocetirizine
- A Mechanistic Study to Evaluate the Efficacy of Montelukast on Airway Function in Asthma
- A Phase 1 Drug-drug Interaction Study in Healthy Volunteers
- A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients
- A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease
- A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial
- A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children
- A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma
- A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
- A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED)
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
- A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
- A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Drugs (11)
- Cinalukast
- CR-3465 Cysteinyl leukotriene receptor 1 antagonist
- CR-3465 FREE ACID Cysteinyl leukotriene receptor 1 antagonist
- Iralukast
- Montelukast Cysteinyl leukotriene receptor 1 antagonist
- Montelukast sodium Cysteinyl leukotriene receptor 1 antagonist
- Pobilukast
- Pranlukast Cysteinyl leukotriene receptor 1 antagonist
- Sulukast
- Verlukast
- Zafirlukast Cysteinyl leukotriene receptor 1 antagonist